Cited by 584Psychedelics and Drug StudiesSubstance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, Teri S, Johansen, Pål-Ørjan·2012·Journal of Psychopharmacology

DOI 10.1177/0269881112439253

Open this paper in CoChat — free account

Abstract

Assessments of lysergic acid diethylamide (LSD) in the treatment of alcoholism have not been based on quantitative meta-analysis. Hence, we performed a meta-analysis of randomized controlled trials in order to evaluate the clinical efficacy of LSD in the treatment of alcoholism. Two reviewers independently extracted the data, pooling the effects using odds ratios (ORs) by a generic inverse variance, random effects model. We identified six eligible trials, including 536 participants. There was evidence for a beneficial effect of LSD on alcohol misuse (OR, 1.96; 95% CI, 1.36–2.84; p = 0.0003). Between-trial heterogeneity for the treatment effects was negligible (I 2 = 0%). Secondary outcomes, risk of bias and limitations are discussed. A single dose of LSD, in the context of various alcoholism treatment programs, is associated with a decrease in alcohol misuse.

Integrity signals

Registry

Crossref · 10.1177/0269881112439253

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Untitled work
(2008) · Cited by 3,790
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“, 2002; McGlothlin, 1964), and in clinical studies the effects of psychedelics are often regarded as highly valued and meaningful (Griffiths et al., 2006; Grob et al., 2011; Studerus et al., 2011).”
Background
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Opioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 762
Alcohol-use disorders
Schuckit, M. A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60009-x · Cited by 715
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · cited 2×
“, 2002; McGlothlin, 1964), and in clinical studies the effects of psychedelics are often regarded as highly valued and meaningful (Griffiths et al., 2006; Grob et al., 2011; Studerus et al., 2011).”
Background
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455

Show all 39 references

Research works printed but not linked: 6

Ables MF, 1967, Highlights of the twelfth annual conference in cooperative studies in psychiatry
Ables MF, 1970, Group treatment of chronic alcoholism with LSD-25: study II. Newsletter for research in psychology, United States Veterans Administration, 12, 17
American Psychiatric Association (1952) Diagnostic and Statistical Manual for Mental Disorders. First Edition. Washington, DC: American Psychiatric Association, 39.
Kurland AA, 1971, Advances in neuropsychopharmacology: proceedings of the 7th congress of the collegium internationale neuro-psychopharmacologicum, 361
Rösner S, 2010, Cochrane Database Syst Rev, 9, CD004332
Rösner S, 2010, Cochrane Database Syst Rev, 12, CD001867

Sorted by citations

Items 201–300 of 584

Psychedelics and dissociative substances
WINSTOCK, A. R., & Rucker, J. (2020) · doi:10.1093/med/9780198713005.003.0054 · Cited by 29
Toward a New Science of Psychedelic Social Psychology: The Effects of MDMA (Ecstasy) on Social Connection
Lyubomirsky, S. (2022) · Perspectives on Psychological Science · doi:10.1177/17456916211055369 · Cited by 34
Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models
Kyzar, E. J., & Kalueff, A. V. (2016) · Zebrafish · doi:10.1089/zeb.2016.1251 · Cited by 31
Treating drug dependence with the aid of ibogaine: A qualitative study
Schenberg, E. E., Comis, M. A. D. C., Alexandre, J. F. M., Chaves, B. R., Tófoli, L. F., & da Silveira, D. X. (2017) · Journal of Psychedelic Studies · doi:10.1556/2054.01.2016.002 · Cited by 29
A role for the serotonin 2A receptor in the expansion and functioning of human transmodal cortex
Luppi, A. I., Girn, M., Rosas, F. E., Timmermann, C., Roseman, L., Erritzøe, D., Nutt, D., Stamatakis, E. A., Spreng, R. N., Xing, L., et al. (2023) · Brain · doi:10.1093/brain/awad311 · Cited by 31
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 33
Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center
Rush, B. R., Marcus, O., García, S., Loizaga-Velder, A. K., Loewinger, G. C., Spitalier, A., & Mendive, F. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.659644 · Cited by 32
Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential
Rucker, J. (2015) · BMJ · doi:10.1136/bmj.h2902 · Cited by 28
Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics
Mason, N. L., & Kuypers, K. P. C. (2018) · Journal of Psychedelic Studies · doi:10.1556/2054.2018.006 · Cited by 28
Dose-response relationships of LSD-induced subjective experiences in humans
Hirschfeld, T., Prugger, J., Majić, T., & Schmidt, T. T. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01588-2 · Cited by 29
Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy
Mocanu, V., Mackay, L., Christie, D., & Argento, E. (2022) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-022-00468-0 · Cited by 31
A Gratuitous Grace: The Influence of Religious Set and Intent on the Psychedelic Experience
Neitzke‐Spruill, L., & Glasser, C. L. (2018) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2018.1494869 · Cited by 27
Altered States of Consciousness and Transpersonal Psychology
Garcia‐Romeu, A., Richard, J., Zech, J. M. S., & Tart, C. T. (2013) · doi:10.1002/9781118591277.ch6 · Cited by 27
Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis
Irizarry, R., Winczura, A., Dimassi, O., Dhillon, N., Minhas, A., & Larice, J. (2022) · Cureus · doi:10.7759/cureus.31796 · Cited by 26
Treating Addiction
Tófoli, L. F., & de Araújo, D. B. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.06.005 · Cited by 35
Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder
Myran, D. T., Pugliese, M., Xiao, J., Kaster, T. S., Husain, M. I., Anderson, K. K., Fabiano, N., Wong, S., Fiedorowicz, J. G., Webber, C., et al. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.3532 · Cited by 25
The Missing Piece? A Case for Microglia’s Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics
VanderZwaag, J., Halvorson, T., Dolhan, K., Šimončičová, E., Ben‐Azu, B., & Tremblay, M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03772-0 · Cited by 28
Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder
Heinzerling, K. G., Sergi, K., Linton, M., Rich, R., Youssef, B., Bentancourt, I., Bramen, J. E., Siddarth, P., Schwartzberg, L., & Kelly, D. F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1215972 · Cited by 25
The Heffter Research Institute: Past and Hopeful Future
Nichols, D. E. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.873688 · Cited by 25
A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder
Celik, M., Gold, M. S., & Fuehrlein, B. (2024) · Brain Sciences · doi:10.3390/brainsci14030294 · Cited by 25
Personal psychedelic experience of psychedelic therapists during training: should it be required, optional, or prohibited?
Villiger, D. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2357669 · Cited by 27
Effects of 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine on alcohol consumption in Long–Evans rats
Berquist, M. D., & Fantegrossi, W. E. (2021) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000628 · Cited by 24
The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being - An Early Review
Bornemann, J. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1761573 · Cited by 24
Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial
O'Donnell, K. C., Mennenga, S. E., Owens, L. T., Podrebarac, S. K., Baron, T., Rotrosen, J., Ross, S., Forcehimes, A. A., & Bogenschutz, M. P. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106976 · Cited by 23
Perceptions of the medicinal value of hallucinogenic drugs among college students
Wildberger, J., John, C. N., & Hallock, R. M. (2017) · Journal of Psychedelic Studies · doi:10.1556/2054.01.2017.008 · Cited by 23
Psychedelic drugs for psychiatric disorders
da Costa, S. C., Oesterle, T., Rummans, T. A., Richelson, E., & Gold, M. S. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120332 · Cited by 32
Correlating the Metabolic Stability of Psychedelic 5-HT2A Agonists with Anecdotal Reports of Human Oral Bioavailability
Leth‐Petersen, S., Bundgaard, C., Hansen, M. A., Carnerup, M. A., Kehler, J., & Kristensen, J. L. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1253-y · Cited by 24
Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money
Humphreys, K. N., Korthuis, P. T., Stjepanović, D., & Hall, W. (2024) · Annual Review of Psychology · doi:10.1146/annurev-psych-020124-023532 · Cited by 26
If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics
Dworkin, R. H., Anderson, B. T., Andrews, N., Edwards, R. R., Grob, C. S., Ross, S., Satterthwaite, T. D., & Strain, E. C. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.05.003 · Cited by 22
The use of classic psychedelics among adults: a Danish online survey study
Juul, T. S., Jensen, M. E., & Fink‐Jensen, A. (2022) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2022.2125069 · Cited by 25
Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder
Kiluk, B. D., Kleykamp, B. A., Comer, S. D., Griffiths, R. R., Huhn, A. S., Johnson, M. W., Kampman, K. M., Pravetoni, M., Preston, K. L., Vandrey, R. G., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.4020 · Cited by 23
Psychedelic Targeting of Metabotropic Glutamate Receptor 2 and Its Implications for the Treatment of Alcoholism
Domanegg, K., Sommer, W. H., & Meinhardt, M. W. (2023) · Cells · doi:10.3390/cells12060963 · Cited by 24
The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis
Sicignano, D. J., Hernández, A. V., Schiff, B., Elmahy, N., & White, C. M. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2296968 · Cited by 22
Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study
Family, N., Hendricks, P. S., Williams, L. T. J., Luke, D. P., Maillet, É. L., Maillet, É. L., & Raz, S. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069103 · Cited by 23
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 27
The psychedelic renaissance: the next trip for psychiatry?
Kelly, J. R., Baker, A., Babiker, M., Burke, L., Brennan, C., & O’Keane, V. (2019) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2019.39 · Cited by 21
Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)
Jensen, M. E., Stenbæk, D. S., Juul, T. S., Fisher, P. M., Ekstrøm, C. T., Knudsen, G. M., & Fink‐Jensen, A. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-066019 · Cited by 25
Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans
Armstrong, S. B., Xin, Y., Sepeda, N. D., Polanco, M., Averill, L. A., & Davis, A. K. (2023) · Military Psychology · doi:10.1080/08995605.2022.2156200 · Cited by 24
The psychedelic effects of cannabis: A review of the literature
Wolinsky, D., Barrett, F. S., & Vandrey, R. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231209194 · Cited by 26
The philosophy of psychedelic transformation
Letheby, C. (2017) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · doi:10.4225/55/5900324d2ad60 · Cited by 23
Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study
Jensen, M. E., Stenbæk, D. S., Messell, C., Poulsen, E. D., Varga, T. V., Fisher, P. M., Nielsen, M. K. K., Johansen, S. S., Volkow, N. D., Knudsen, G. M., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251319457 · Cited by 22
Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis
Højlund, M., Kafalı, H. Y., Kırmızı, B., Fusar‐Poli, P., Correll, C. U., Cortese, S., Sabé, M., Fiedorowicz, J. G., Saraf, G., Zein, J., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.09.011 · Cited by 23
Turn on and tune in to evidence-based psychedelic research
Sessa, B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00120-5 · Cited by 22
Hallucinogens and Their Therapeutic Use: A Literature Review
Begola, M. J., & Schillerstrom, J. E. (2019) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000409 · Cited by 20
Cardiovascular effects and safety of classic psychedelics
Nahlawi, A., Ptaszek, L. M., & Ruskin, J. N. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00608-2 · Cited by 19
Psychedelics in the Treatment of Substance Use Disorders and Addictive Behaviors: A Scoping Review
Richard, J., & Garcia‐Romeu, A. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00629-8 · Cited by 22
Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice
Elsilä, L. V., Harkki, J., Enberg, E., Martti, A., Linden, A.-M., & Korpi, E. R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221104641 · Cited by 21
The current state of ayahuasca research in animal models: A systematic review
Daldegan‐Bueno, D., Simionato, N. M., Favaro, V. M., & Maia, L. O. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110738 · Cited by 21
Reduction of alcohol use and increase in psychological flexibility after a naturalistic psychedelic experience: a retrospective survey
Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., Roméo, B., & Benyamina, A. (2023) · Alcohol and Alcoholism · doi:10.1093/alcalc/agad078 · Cited by 22
Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future
Nutt, D. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675754 · Cited by 19
Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder
Lee, Y. K., Gold, M. S., & Fuehrlein, B. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120094 · Cited by 20
The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials
Hogea, L., Tabugan, D. C., Costea, I., Albai, O., Nussbaum, L. A., Cojocaru, A., Corsaro, L., & Anghel, T. (2025) · Medicina · doi:10.3390/medicina61020278 · Cited by 19
A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment
Burdick, B. V., & Adinoff, B. H. (2013) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2013.811513 · Cited by 19
It’s time to take psilocybin seriously as a possible treatment for substance use disorders
Bogenschutz, M. P. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1200060 · Cited by 18
HERE AND NOW: DISCOVERING THE SACRED WITH ENTHEOGENS
Richards, W. A. (2014) · Zygon® · doi:10.1111/zygo.12108 · Cited by 18
Psychédéliques, psychothérapie et symbolisation : une revue de littérature dans le champ de la dépression
Artru, E., & Rabeyron, T. (2021) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2021.03.013 · Cited by 20
Impact of a Naturalistic Psychedelic Experience on Smoking: A Retrospective Survey
Roméo, B., Fauvel, B., Dejean, S., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2227171 · Cited by 17
Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey
Glynos, N. G., Aday, J. S., Kruger, D. J., Boehnke, K. F., Lake, S., & Lucas, P. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1349565 · Cited by 17
The potential of 5‐methoxy‐ N,N ‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action
Tap, S. C. (2024) · Addiction Biology · doi:10.1111/adb.13386 · Cited by 16
Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges
Gomez-Escolar, A., Folch‐Sanchez, D., Stefaniuk, J., Swithenbank, Z., Nisa, A., Braddick, F., Chaudhary, N. I., van der Meer, P. B., & Batalla, A. (2024) · CNS Drugs · doi:10.1007/s40263-024-01101-3 · Cited by 21
Sociological investigations of human enhancement drugs: The case of microdosing psychedelics
Liokaftos, D. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.103099 · Cited by 17
Psychosocial and Drug Use Assessment of Regular vs. Non-Regular Ayahuasca Users in a Brazilian Sample: a Web-Based Survey
Daldegan‐Bueno, D., Révész, D., Morais, P. R., Barbosa, P. C. R., & Maia, L. O. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2022.2063896 · Cited by 20
Blinding and expectancy confounds in psychedelic randomised controlled trials
Muthukumaraswamy, S., Forsyth, A., & Lumley, T. (2021) · doi:10.31234/osf.io/q2hzm · Cited by 15
The Psychological Flexibility Model from a cultural perspective: An interpretative analysis of two Native American healing rituals
Sabucedo, P. (2017) · International Journal of Culture and Mental Health · doi:10.1080/17542863.2017.1323935 · Cited by 16
Psychedelics and environmental virtues
Kirkham, N., & Letheby, C. (2022) · Philosophical Psychology · doi:10.1080/09515089.2022.2057290 · Cited by 20
How Drug Control Policy and Practice Undermine Access to Controlled Medicines.
Burke-Shyne, N., Csete, J., Wilson, D., Fox, E., Wolfe, D., & Rasanathan, J. (2017) · Europe PMC (PubMed Central) · Cited by 16
Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review
Zhornitsky, S., Oliva, H. N. P., Jayne, L. A., Allsop, A. S., Kaye, A. P., Potenza, M. N., & Angarita, G. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1197890 · Cited by 15
Integrative Pharmacology in the Treatment of Substance Use Disorders
Donlon, J., Kumari, P., Varghese, S. P., Bai, M. Y., Florentin, O. D., Frost, E. D., Banks, J., Vadlapatla, N., Kam, O., Shad, M. U., et al. (2023) · Journal of Dual Diagnosis · doi:10.1080/15504263.2023.2293854 · Cited by 15
Psychedelics and schizophrenia: a double-edged sword
Sapienza, J., Martini, F., Comai, S., Cavallaro, R., Spangaro, M., Gregorio, D. D., & Bosia, M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02743-x · Cited by 20
A dangerous method? Psychedelic therapy at Modum Bad, Norway, 1961–76
Johnstad, P. G. (2020) · History of Psychiatry · doi:10.1177/0957154x19894537 · Cited by 15
Connected to the spirit of the frog: An Internet-based survey on Kambô, the secretion of the Amazonian Giant Maki Frog (Phyllomedusa bicolor): Motivations for use, settings and subjective experiences
Majić, T., Sauter, M., Bermpohl, F., & Schmidt, T. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121991554 · Cited by 14
Effectiveness of Psilocybin on Depression: A Qualitative Study
Alshaikhli, H., Al-Naggar, R. A., & Erlam, G. D. (2021) · Electronic Journal of General Medicine · doi:10.29333/ejgm/10862 · Cited by 21
Psychedelics, Mystical Experiences, and Meaning Making: A Renegotiation Process With the Challenges of Existence
Hearn, B. (2021) · The Journal of Humanistic Counseling · doi:10.1002/johc.12164 · Cited by 18
Psychedelic drugs in the treatment of anxiety, depression and addiction
Kvam, T.-M., Stewart, L. H., & Andreassen, O. A. (2018) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.1110 · Cited by 15
The association between naturalistic use of psychedelics and co-occurring substance use disorders
Rabinowitz, J., Lev‐Ran, S., & Gross, R. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1066369 · Cited by 15
Ayahuasca Treatment Outcome Project (ATOP): One-Year Results from Takiwasi Center and Implications for Psychedelic Science
Rush, B. R., Marcus, O., García, S., Loizaga-Velder, A. K., Spitalier, A., & Mendive, F. M. (2023) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.23-00005 · Cited by 14
Psychedelics, epilepsy, and seizures: a review
Freidel, N., Kreuder, L., Rabinovitch, B. S., Chen, F. Y., Huang, R. S., & Lewis, E. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1326815 · Cited by 14
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction
Vamvakopoulou, I. A., & Nutt, D. J. (2024) · European Addiction Research · doi:10.1159/000540062 · Cited by 18
Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial
Vanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05502-y · Cited by 13
“Moreover, treatment comparison indicated a larger reduction in alcohol misuse and greater abstinence rates with LSD treatment than with commonly used AUD medication (i.e., naltrexone, acamprosate, and disulfiram) [14].”
Method
Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer
Barnett, B. S., & Greer, G. R. (2021) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2020.12.011 · Cited by 13
Psilocybin or Nicotine Patch for Smoking Cessation
Johnson, M. W., Naudé, G. P., Hendricks, P. S., & Garcia‐Romeu, A. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.0972 · Cited by 14
The role of brain serotonin signaling in excessive alcohol consumption and withdrawal: A call for more research in females
Castle, M., & Flanigan, M. E. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2024.100618 · Cited by 13
Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties
Atiq, M. A., Baker, M. R., Voort, J. L. V., Vargas, M. V., & Choi, D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06599-5 · Cited by 16
History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers
Barber, M., Gardner, J., & Carter, A. (2024) · Journal of Bioethical Inquiry · doi:10.1007/s11673-024-10386-4 · Cited by 13
Integrating complementary and alternative therapies into professional psychological practice: An exploration of practitioners’ perceptions of benefits and barriers
Kassis, A., & Papps, F. A. (2020) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2020.101238 · Cited by 13
IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models
Yaden, D. B., Berghella, A. P., Hendricks, P. S., Yaden, M. E., Levine, M., Rohde, J. S., Nayak, S. M., Johnson, M. W., & Garcia‐Romeu, A. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106998 · Cited by 13
The potential utility of some legal highs in CNS disorders
Davidson, C., & Schifano, F. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.07.010 · Cited by 13
Mind‐altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?
Nutt, D. (2014) · EMBO Reports · doi:10.1002/embr.201338282 · Cited by 15
Research ethics aspects of experimentation with LSD on human subjects: a historical and ethical review
Bodnár, J. K., & Kakuk, P. (2018) · Medicine Health Care and Philosophy · doi:10.1007/s11019-018-9871-9 · Cited by 13
Human behavioral pharmacology of psychedelics
Strickland, J. C., & Johnson, M. W. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2021.10.003 · Cited by 16
Christianity and Psychedelic Medicine: A Pastoral Approach
McCarthy, B. C. (2022) · Christian bioethics Non-Ecumenical Studies in Medical Morality · doi:10.1093/cb/cbac008 · Cited by 14
Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD)
Beutler, B. D., Shinozuka, K., Tabaac, B. J., Arenas, A., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001726 · Cited by 13
Psychedelics as Reemerging Treatments for Anxiety Disorders: Possibilities and Challenges in a Nascent Field
King, F., & Hammond, R. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200047 · Cited by 14
Molecular and structural insights into the 5‐HT 2C receptor as a therapeutic target for substance use disorders
Ubhayarathna, M., Langmead, C. J., Diepenhorst, N. A., & Stewart, G. D. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16233 · Cited by 12
Exploring the effect of microdosing psychedelics on creativity in an open-label natural settingPreprint
Prochazkova, L., Lippelt, D. P., Colzato, L. S., Kuchař, M., Sjoerds, Z., & Hommel, B. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/384412 · Cited by 12
Associations between psychedelic use and cannabis use disorder in a nationally representative sample
Zech, J. M., Yaden, D. B., & Jones, G. M. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.112502 · Cited by 11
Psilocybin Dispensaries and Online Health Claims in Canada
Matsukubo, J., Dickson, S., Xiao, J., Friesen, E. L., Solmi, M., Fiedorowicz, J. G., Fischer, B., & Myran, D. T. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.2853 · Cited by 11
Ibogaine Blocks Cue- and Drug-Induced Reinstatement of Conditioned Place Preference to Ethanol in Male Mice
Henriques, G. M., Anjos-Santos, A., Rodrigues, I. R. S., Nascimento-Rocha, V., Reis, H. S., Libarino-Santos, M., Barros-Santos, T., Yokoyama, T. S., Bertagna, N. B., Favoretto, C. A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739012 · Cited by 12
Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders
Martins, B. S., Rutland, W., Aquino, J. P. D., Kazer, B., Funaro, M. C., Potenza, M. N., & Angarita, G. A. (2022) · Current Addiction Reports · doi:10.1007/s40429-022-00432-9 · Cited by 12
The possible place for psychedelics in pharmacotherapy of mental disorders
Wojtas, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00550-9 · Cited by 12

Authors: Krebs, T. S., & Johansen, P.-Ø.
Affiliations: Harvard University (US)
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2012-03-08
Volume: 26
Issue: 7
Pages: 994-1002
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881112439253
OpenAlex: W1973613743
Cited by: 583
References: 39
Citations by year: 2026: 39 · 2025: 55 · 2024: 67 · 2023: 63 · 2022: 59 · 2021: 52 · 2020: 55 · 2019: 25 · 2018: 34 · 2017: 29 · 2016: 31 · 2015: 25 · 2014: 23 · 2013: 19 · 2012: 6
FWCI: 3.40
Type: journal article
Language: en
Open access: closed
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: lysergic acid diethylamide, LSD, alcoholism, alcohol abuse, psychedelic therapy, alcoholism treatment, treatment efficacy
MeSH terms: Adult, Alcoholism, Combined Modality Therapy, Hallucinogens, Humans, Lysergic Acid Diethylamide, Randomized Controlled Trials as Topic, Substance Abuse Treatment Centers, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks